PVLA
Palvella Therapeutics Inc.
$98.58
+$1.80(+1.86%)
54
Overall
40
Value
66
Tech
57
Quality
Market Cap
$937.64M
Volume
189.13K
52W Range
$11.17 - $106.71
Target Price
$127.67
Company Overview
| Mkt Cap | $937.64M | Price | $98.58 |
| Volume | 189.13K | Change | +1.86% |
| P/E Ratio | -53.8 | Open | $97.81 |
| Revenue | -- | Prev Close | $96.78 |
| Net Income | $-17.4M | 52W Range | $11.17 - $106.71 |
| Div Yield | N/A | Target | $127.67 |
| Overall | 54 | Value | 40 |
| Quality | 57 | Technical | 66 |
No chart data available
About Palvella Therapeutics Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Latest News
Analysts Are Bullish on Top Healthcare Stocks: Adicet Bio (ACET), Palvella Therapeutics (PVLA)
Howard Kim•9 days ago
Palvella Therapeutics (PVLA) Gets a Buy from LifeSci Capital
TipRanks Auto-Generated Intelligence Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PVLA | $98.58 | +1.9% | 189.13K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Palvella Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW